Tamoxifen citrate and anastrozole citrate passed the consistency evaluation

Recently, tamoxifen citrate tablets (10mg) and anastrozole tablets (1mg) of Yangzijiang pharmaceutical group passed the quality and efficacy evaluation of generic drugs In addition to surgery, the treatment of breast cancer also includes endocrine therapy, radiotherapy, chemotherapy and targeted therapy Tamoxifen citrate and anastrozole are commonly used endocrine therapy drugs for breast cancer Tamoxifen citrate is mainly used in the treatment of recurrent and metastatic breast cancer in women, as well as adjuvant treatment of postoperative metastasis of breast cancer In 2015, it was recommended by the ago guidelines to use first-line drugs to assist in the treatment of postmenopausal HER2 negative metastatic breast cancer after AI, and in 2017, it was included in the new version of China's national medical insurance catalog Anatrazole tablets are mainly used in the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer It can inhibit the production of androstenedione into estrone in the adrenal gland of postmenopausal patients, thus significantly reduce the level of plasma estrogen, inhibit the growth of breast cancer, and obtain the consensus of many authoritative experts and the recommendation of diagnosis and treatment guidelines Since 2014, Yangzijiang Pharmaceutical Group has adhered to the highest standard to promote the consistency evaluation of quality and efficacy of generic drugs It has started the re evaluation of more than 60 chemical generic drugs At present, the number of products through the consistency evaluation has reached 8, and more than 20 varieties have completed the application and are in the evaluation state.